Ablation Techniques for Atrial Fibrillation

(PVI-PLUS Trial)

This trial tests whether adding extra steps to a heart procedure can benefit people with persistent atrial fibrillation (AF), a condition where the heart beats fast and irregularly. It compares two approaches: the usual procedure targeting specific heart veins (PVI) and a more detailed one that includes additional heart areas (PWI and SVCI). The goal is to determine if the extra steps improve results by maintaining a steady heart rhythm for a year without medication. Individuals who have experienced persistent AF episodes lasting more than a week and are interested in heart procedure monitoring may be suitable candidates. As an unphased trial, this study provides a unique opportunity for patients to contribute to innovative research that could enhance future heart procedures.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that pulsed field ablation (PFA) for treating atrial fibrillation (AF) is generally well-tolerated. For example, studies have found that isolating the back wall of the heart (posterior wall isolation) during AF treatment is safe and carries a low risk of complications. When combined with pulmonary vein isolation, PFA has proven effective and safe for many patients, with about 63.5% experiencing successful treatment after one year. Additionally, only a small number of patients experienced isolated episodes of AF, indicating that serious side effects are uncommon. Overall, the evidence supports the safety of combining these procedures with PFA.¹²³⁴⁵

Researchers are excited about the ablation techniques for atrial fibrillation (Afib) because they combine multiple approaches to potentially improve outcomes. Unlike the standard pulmonary vein isolation (PVI) alone, this technique includes posterior wall isolation (PWI) and superior vena cava isolation (SVCI). These additional steps could lead to more effective disruption of abnormal electrical signals in the heart, which may reduce the recurrence of Afib. By addressing multiple areas of the heart, this comprehensive approach might offer a more robust solution compared to current treatments that focus solely on PVI.

Research shows that Pulmonary Vein Isolation (PVI) effectively manages atrial fibrillation (AF), particularly when it occurs occasionally. In this trial, one group of participants will receive only PVI. However, for persistent AF, PVI alone might not always prevent the irregular heartbeat from returning. Another group in this trial will receive a combination of PVI, Posterior Wall Isolation (PWI), and Superior Vena Cava Isolation (SVCI), which studies suggest can lead to better outcomes. Pulsed field ablation, a type of energy used in these procedures, has proven to be 63.5% effective in reducing atrial fibrillation after one year. Observational data also supports the safety and practicality of these combined procedures.¹²³⁴⁶